Tumor burden modeling versus progression-free survival for phase II decision making

Clinical Cancer Research

Volumn 19, Issue 2, 2013, Pages 314-319

  Kaiser, Lee D ^a  

^a Endocrinology and Internal Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PACLITAXEL; PLACEBO; TRASTUZUMAB;

ANALYTICAL PARAMETERS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SIZE; COLORECTAL CANCER; DRUG RESPONSE; DYNAMICS; HUMAN; LOG RANK TEST; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; NONLINEAR SYSTEM; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANK SUM TEST; SIMULATION; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SUM OF LONGEST DIAMETER; TUMOR VOLUME;

CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; DISEASE-FREE SURVIVAL; HUMANS; MODELS, STATISTICAL; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR BURDEN;

EID: 84872577135     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2161     Document Type: Article

References (32)

1. Brown SR, Gregory WM, Twelves CJ, Buyse M, Collinson F, Parmar M, et al. Designing phase II trials in cancer: a systematic review and guidance. Br J Cancer 2011;105: 194-199.
2. Cannistra SA. Phase II trials in journal of clinical oncology. J Clin Oncol 2009;27: 3073-3076.
3. Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: the importance of randomization. Eur J Cancer 2009;45: 275-280.
4. Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005;23: 7199-7206.
5. Tang H, Foster NR, Grothey A, Ansell SM, Goldberg RM, Sargent DJ. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol 2010;28: 1936-41.
6. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228-47.
7. Rubinstein L, Crowley J, Ivy P, LeBlanc M, Sargent D. Randomized phase II designs. Clin Cancer Res 2009;15: 1883-90.
8. Sharma MR, Stadler WM, Ratain MJ. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst 2011;103: 1093-1100.
9. Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change of tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 2007;99: 1455-61.
10. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24: 2505-12.
11. Buyse M, Quinaux E, Hendlisz A, Golfinopoulos V, Tournigand C, Mick R. Progression-free survival ratio as end point for phase II trials in advanced solid tumors. J Clin Oncol 2011;29:e451-e452.
12. Wang Y, Sung C, Dartois C, Ramchandani R, Booth BP, Rock E, et al. Elucidation of relationship between tumor size and survival in nonsmall- cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 2009;86: 167-74.
13. Claret L, Girard P, Hoff PM, Van CutsemE, Zuideveld KP, Jorga K, et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 2009;27: 4103-8.
14. Bruno R, Claret L. On the use of change in tumor size to predict survival in clinical oncology studies: towards a new paradigm to design and evaluate phase II studies. Clin Pharmacol Ther 2009;86: 136-8.
15. Stein A, Wang W, Carter A, Chiparus O, Hollaender N, Motzer R, et al. Dynamic tumor modelling of the RECORD-1 phase II trial of everolimus quantifies relationship between dose and tumor growth in metastatic renal cell carcinoma. Eur Urol Suppl 2011;10:232.
16. Stein WD, Yang J, Bates SE, Fojo T. Bevacizumab reduces the growth rate constants of renal carcinomas: A novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. The Oncologist 2008;13: 1055-62.
17. Stein WD, Huang H, Menefee M, Edgerly M, Kotz H, Dwyer A, et al. Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma. Cancer J 2009;15: 441-7.
18. Fojo AT, Stein WD, Wilkerson J, Bates SE. Kinetic analysis of breast tumor decay and growth following ixabepilone plus capecitabine (IXA+ CAP) versus capecitabine alone (CAP) to discern whether the superiority of the combination is a result of slower growth, enhanced tumor cell kill, or both. J Clin Onc 28:15s, 2010 (suppl; abstr 1096).
19. Fridlyand J, Kaiser LD, Fyfe G. Analysis of tumor burden versus progression-free survival for phase II decision making. Contemp Clin Trials 2011;32: 446-52.
20. Sharma MR, Karrison TG, Jin Y, Bies RR, Maitland ML, Stadler WM, et al. Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res 2012;18: 2309-15.
21. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. NEngl J Med 2004;350: 2335-42.
22. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23: 792-9.
23. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005;23: 3697-705.
24. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub J-P, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20: 2812-23.
25. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer.NEngl J Med 2005;353: 123-32.
26. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344: 783-92.
27. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47: 207-14.
28. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 2005;49: 1020-38.
29. Monolix: A software for the analysis of nonlinear mixed effects models. [cited 2012 Jun 19]. Available from http://www.lixoft.com/wp-content/ resources/docs/UsersGuide.pdf.
30. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009;101: 1642-9.
31. Rubinstein LV, Dancey JE, Korn EL, Smith MA, Wright JJ. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise? J Natl Cancer Inst 2007;99: 1422-3.
32. Mietlowski WL, Bao W, Wood PA, Williams DE, El-Hashimy M, Sarr C, et al. Clinical importance of including new and nontarget lesion assessment of disease progression (PD) to predict overall survival (OS): implications for randomized phase II study design. J Clin Oncol 30:15s, 2012 (suppl; abstr 2543).